The Food and Drug Administration (FDA) approved cetuximab, a monoclonal antibody targeting the EGFR, for HNSCC patients in 2006, yet the clinical response to EGFR inhibition remains modest, despite the nearly ubiquitous EGFR overexpression in HNSCC tumors. Here, EGFR is linked to head and neck squamous cell carcinoma.